Ipratropiumbromid Hexal

Ipratropium bromide, the active ingredient in Ipratropiumbromid Hexal, is an anticholinergic (muscarinic antagonist) presented as an inhalation solution for inhalation use. It is employed to relieve bronchoconstriction in patients with chronic obstructive pulmonary disease, asthma and other forms of bronchospasm.

GNH USA supplies Ipratropiumbromid Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Ipratropium bromide is a bronchodilator that acts on the muscarinic pathways of the respiratory system.

- Chronic obstructive pulmonary disease (COPD): improves airflow and reduces exacerbations. - Asthma: provides additional bronchodilation when used with other controllers. - Bronchospasm: rapidly relieves acute airway narrowing.

Ipratropium bromide may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dry mouth - Cough - Throat irritation - Headache - Dizziness - Taste disturbance

Serious or Rare Side Effects: - Paradoxical bronchospasm - Severe allergic reaction (anaphylaxis) - Angioedema - Respiratory depression - Urinary retention - Increased intraocular pressure

When prescribing Ipratropium bromide, clinicians should consider several safety measures.

- Assess respiratory status: confirm diagnosis of COPD or asthma before initiation. - Monitor for anticholinergic effects: watch for dry mouth, urinary retention, especially in elderly patients. - Avoid use in patients with narrow‑angle glaucoma: risk of increased intraocular pressure. - Caution in patients with bladder outlet obstruction: possible urinary retention. - Do not combine with other anticholinergic inhalers without medical guidance. - Store at room temperature: keep in original packaging, protect from moisture.

Ipratropium bromide can interact with other medications, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concurrent use of other anticholinergic agents (e.g., tiotropium) may increase anticholinergic burden. - High‑dose beta‑agonist inhalers may mask inadequate response, leading to overreliance.

Moderate Interactions (Monitor Closely): - Use with inhaled corticosteroids may enhance bronchodilation but requires monitoring for local irritation. - Systemic anticholinergics (e.g., atropine) may potentiate side effects. - Patients on cholinesterase inhibitors for myasthenia gravis may experience reduced therapeutic effect.